NRXPW
NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -0.3%
- EBIT
- +2.1%
- EPS
- +38.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -15.7%
- EBIT
- +17.7%
- Net income
- -13.9%
- EPS
- +43.9%
- Free cash flow
- -32.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026